Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Next Previous
Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
  • Indications Atherosclerosis; Cardiovascular disorders; Hyperlipidaemia; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms FOURIER; PROFICIO
  • Sponsors Amgen

Most Recent Events

  • 31 Oct 2025 According to Amgen media release, analyses comparing data from this study to a FOURIER Like-External Control Arm Using Real-World Data, will be presented at the American Heart Association Scientific Sessions taking place November 7-10, 2025, in New Orleans, LA.
  • 18 Jun 2025 According to an Amgen media release, data from this study will be presented at the 85th American Diabetes Association (ADA) Scientific Sessions taking place from June 20-23, 2025, in Chicago.
  • 18 Nov 2024 Results discussing Association Between Lipoprotein(a) Levels and Incident Complex Coronary Revascularization Procedures , presented at the American Heart Association Scientific Sessions 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top